臨床婦人科産科68巻3号

2014年04月発行

今月の臨床 メタボとロコモ―これからの女性医療のキーワード 女性のロコモティブ症候群 2．骨粗鬆症

3）骨粗鬆症の治療薬

著者： 倉林工¹

所属機関： ¹新潟市民病院産婦人科

ページ範囲：P.342 - P.350

●女性の生涯に関連する骨粗鬆症は，「女性医学」の関心領域のなかでも太い“骨格”の1つである．

●閉経後骨粗鬆症治療の第一選択薬はビスホスホネート製剤とSERM製剤である．

●閉経直後で更年期障害がある場合には，副作用に注意しつつホルモン補充療法の選択も可能である．

●単剤で効果がない場合や高齢者では活性型ビタミンD₃製剤の併用も有用である．

参考文献

1） 日本産科婦人科学会 編 : 産科婦人科用語集・用語解説集改訂第3版．日本産科婦人科学会，2013

2） Siris ES, Chen YT, Abbott TA, et al : Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164 : 1108-1112, 2004

3） McClung MR, Geusens P, Miller PD, et al : Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 : 333-340, 2001

4） Hochberg MC, Thompson DE, Black DM, et al : Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20 : 971-976, 2005

5） Bone HG, Hosking D, Devogelaer JP, et al : Ten year’s experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189-1199, 2004

6） Whitaker M, Guo J, Kehoe T, et al : Bisphosphonates for Osteoporosis-Where Do We Go from Here? N Engl J Med 366 : 2048-2051, 2012

7） Odvina CV, Zerwekh JE, Rao DS, et al : Severely suppressed bone turnover : A potential complication of alendronate therapy. J Clin Endocrinol Metab 90 : 1294-1301, 2005

8） Yoneda T, Hagino H, Sugimoto T, et al : Bisphosphonate-Related Osteonecrosis of the Jaw : Position Paper from the Allied Task Force. Committee of Japanese Society for Bone and Mineral Research, Osteoporosis Society Japan, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28 : 365-383, 2010

9） ビスフォスフォネート関連顎骨壊死検討委員会 : ビスフォスフォネート関連顎骨壊死に対するポジションペーパー（改訂追補2012年版）．http://jsbmr.umin.jp/pdf/BRONJpositionpaper2012.pdf

10） Ettinger B, Black DM, Mitlak BH, et al : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation（MORE） Investigators. JAMA 282 : 637-645, 1999

11） Siris ES, Harris ST, Eastell R, et al : Skeletal effects of raloxifene after 8 years : results from the continuing outcomes relevant to Evista（CORE） study. J Bone Miner Res 20 : 1514-1524, 2005

12） Kanis JA, Johnell O, Black DM, et al : Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis : a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33 : 293-300, 2003

13） Silverman SL, Chines AA, Kendler DL, et al : Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis : results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23 : 351-363, 2012

14） Cadarette SM, Katz JN, Brookhart MA, et al : Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148 : 637-646, 2008

15） Recker R, Kendler D, Recknor CP, et al : Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 40 : 843-851, 2007

16） Allen MR, Gineyts E, Leeming DJ, et al : Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 19 : 329-337, 2008

17） Saito M, Marumo K, Soshi S, et al : Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int 21 : 655-666, 2010

18） Johnell O, Kanis JA, Black DM, et al : Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation（MORE） Study. J Bone Miner Res 19 : 764-772, 2004

19） Martino S, Cauley JA, Barrett-Connor E, et al : Continuing outcomes relevant to Evista : breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 : 1751-1761, 2004

20） Walsh BW, Kuller LH, Wild RA, et al : Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279 : 1445-1451, 1998

21） Collins P, Mosca L, Geiger MJ, et al : Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial : results of subgroup analyses by age and other factors. Circulation 119 : 922-930, 2009

22） Mosca L, Grady D, Barrett-Connor E, et al : Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 40 : 147-155, 2009

23） Iikuni N, Hamaya E, Nihojima S, et al : Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab 30 : 674-682, 2012

24） Lindsay R : Preventing osteoporosis with a tissue selective estrogen complex（TSEC） containing bazedoxifene/conjugated estrogens（BZA/CE）. Osteoporos Int 22 : 447-451, 2011

25） 日本産科婦人科学会，日本女性医学学会 編 : ホルモン補充療法ガイドライン2012年度版．日本産科婦人科学会，2012

26） Rossouw JE, Anderson GL, Prentice RL, et al : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288 : 321-333, 2002

27） Torgerson DJ, Bell-Syer SE : Hormone replacement therapy and prevention of nonvertebral fracures : a meta-analysis of randomized trials. JAMA 285 : 2891-2897, 2001

28） Mizunuma H, Taketani Y, Ohta H, et al : Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric 13 : 72-83, 2010

29） Notelovitz M, John VA, Good WR : Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause 9 : 343-353, 2002

30） Delmas PD, Confavreux E, Garnero P, et al : A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteopors Int 11 : 177-187, 2000

31） Cetinkaya MB, Kökçü A, Yanik FF, et al : Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women. J Bone Miner Metab 20 : 44-48, 2002

32）Bhattoa HP, Bettembuk P, Balogh A, et al : The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients ; A randomized, doubleblind, placebo-controlled trial. Osteoporos Int 15 : 396-404, 2004

33） Jackson RD, LaCroix AZ, Gass M, et al : Calcium plus vitamin D supplementation and the risk of fractures. N Eng J Med 354 : 669-683, 2006

34） Bischoff HA, Stähelin HB, Dick W, et al : Effects of vitamin D and calcium supplementation on falls : A randomized controlled trial. J Bone Miner Res 18 : 343-351, 2003

35） Mizunuma H, Shiraki M, Shintani M, et al : Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3（alfacalcidol） for treatment of postmenopausal bone loss. J Bone Miner Metab 24 : 11-15, 2006

36） Matsumoto T, Ito M, Hayashi Y, et al : A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-A randomized, active comparator, double-blind study. Bone 49 : 605-612, 2011

37） Neer RM, Arnaud CD, Zanchetta JR,et al : Effect of parathyroid hormone（1-34） on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 : 1434-1441, 2001

38） Nakamura T, Sugimoto T, Nakano T, et al : Randomized Teriparatide［human parathyroid hormone（PTH） 1-34］Once-Weekly Efficacy Research（TOWER） trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97 : 3097-3106, 2012